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Abstract: The impact of longitudinal anthropometric changes during adjuvant chemotherapy on
long-term survival in non-metastatic colon cancer is unclear. Herein, we analyzed the prognostic
significance of computed tomography (CT)-measured body composition changes in colon cancer
patients who underwent surgery followed by adjuvant FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin)
chemotherapy. Data of 167 patients with stage III or high-risk stage II colon cancer were analyzed.
Skeletal muscle index (SMI), skeletal muscle radiodensity (SMR), visceral fat index (VFI), subcutaneous
fat index (SFI), and total fat index (TFI) changes during chemotherapy were calculated using preoperative
and postchemotherapy CT image data. The Cox proportional hazard model was used to determine the
correlation between changes in anthropometric values and overall survival (OS). The median changes
(%) in SMI, SMR, VFI, SFI, and TFI over 210 days during chemotherapy were 8.7% (p < 0.001), 3.4%
(p = 0.001), −19% (p < 0.001), −3.4% (p = 0.936), and −11.9% (p < 0.001), respectively. Cut-off values of
changes in SMI (skeletal muscle index change, SMIC) and SMR (skeletal muscle radiodensity change,
SMRC) were defined at −2% and −2 Hounsfield units (HU) respectively, whereas those of changes in
VFI (visceral fat index change, VFIC), SFI (subcutaneous fat index change, SFIC), and TFI (total fat index
change, TFIC) were based on values that provided the largest χ2 on the Mantel–Cox test. Multivariable
analysis revealed that low SMR measured on a postchemotherapy CT scan (hazard ratio, HR: 0.32, 95%
confidence interval, CI: 0.15–0.70, p = 0.004) and visceral fat loss of at least 46.57% (HR: 0.31, 95% CI:
0.14–0.69, p = 0.004) were independent poor prognostic factors for OS. Severe visceral fat loss during
FOLFOX chemotherapy and low skeletal muscle radiodensity measured on postchemotherapy CT
scans are associated with poor OS in stage III and high-risk stage II colon cancer patients.
Keywords: colon cancer; skeletal muscle; visceral fat; subcutaneous fat; radiodensity; overall survival
1. Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide [1].
Curative resection is the treatment of choice, and adjuvant chemotherapy is recommended for
potentially increasing survival in colon cancer patients diagnosed with stage III and stage II with
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high-risk factors [2]. Although various chemotherapy regimens have been recommended in these cases,
FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) is one of the most commonly used adjuvant
chemotherapy regimens, with clear indications for use in the postoperative setting [3–5]. However,
well-described risk factors to predict mortality after completion of chemotherapy are lacking in these
relatively high-risk groups; therefore, recommendations for identifying ideal candidates for more
intensive follow-up have not been characterized.
The impact of skeletal muscle depletion (known as sarcopenia) or decreased skeletal muscle
radiodensity (known as myosteatosis) has been investigated in various cancers with respect to
chemotherapy- or chemoradiotherapy-induced toxicities or survival [6–10]. Sarcopenia, myosteatosis,
and visceral obesity have demonstrated substantial value as prognosticators in a number of studies on
various cancers including CRC [11–13]. In addition to cross-sectional data-driven analysis, several
studies have investigated the impact of skeletal muscle changes during treatment in patients with
CRC. Skeletal muscle loss during chemotherapy is known to be associated with poorer survival and is
known to predict an increased risk of dose-limiting toxicities, particularly in patients with metastatic or
advanced CRC [14–16]. Previous studies have investigated the prognostic significance of longitudinal
changes in skeletal muscle index (SMI), skeletal muscle radiodensity (SMR), and visceral fat index (VFI)
in patients with non-metastatic CRC, using data from baseline and follow-up computed tomography
(CT) scans. However, in previous studies, the time span between the two CT scans was variable, with
durations of 9–27 months, 24 months, and more than 1 year after surgery or adjuvant chemotherapy;
in addition, patients with early recurrence were not included in certain studies [17–19]. Therefore,
the clinical applicability of these results may be limited in patients with longer survival, who undergo
long-term follow-up CT examinations without recurrences. To date, studies simultaneously analyzing
the impact of longitudinal changes in muscle and fat in this setting are lacking.
Therefore, this study aimed to investigate the prognostic significance of longitudinal changes in
body composition including muscle and fat during adjuvant FOLFOX chemotherapy in patients with
stage III and high-risk stage II colon cancer.
2. Results
We identified a total of 214 patients with colon cancer who were treated with adjuvant FOLFOX
chemotherapy after surgery. Five patients were excluded owing to administration of neoadjuvant
chemotherapy (n = 3) and a history of inflammatory bowel disease (n = 2); thirty-three patients
were excluded owing to missing data or the sub-optimal quality of preoperative CT (n = 9) or
postchemotherapy CT scans (n = 24). Among those who underwent CT measurements, patients with
intestinal obstruction showing on their preoperative CT scans (n = 9) were excluded as data on correct
measurements of visceral fat were limited in these cases. Among the 214 patients, 167 had met the
defined criteria and constituted our study sample. Among the included patients, 137 patients (82%)
completed 12 cycles of chemotherapy, and 95% of patients underwent more than six cycles of FOLFOX
chemotherapy (Supplementary Figure S1).
The baseline characteristics of the patients, based on their gender, are presented in Table 1. Among
167 patients, 67 were female and 100 were male. There were no differences in clinicopathological variables
between female and male subgroups, except body mass index (BMI). The proportion of patients who
had a BMI exceeding 25 kg/m2 and who were smokers was significantly higher in the male than in the
female subgroup (34% vs. 17.9%, p = 0.035 and 47% vs. 0%, p < 0.001, respectively).
Absolute changes in body composition during FOLFOX adjuvant chemotherapy were evaluated
according to each variable. SMI and SMR increased (p < 0.001 and p = 0.001, respectively), and VFI
decreased significantly (p < 0.001); however, there was no change in SFI (p = 0.936) (Supplementary
Tables S1 and S2). Anthropometric values measured using preoperative and postchemotherapy CT scans
and their changes over 210 days were compared between patients from either gender. The mean values of
SMI_pre, SMR_pre, and VFI_pre were significantly higher in the male than the female subgroup, whereas
SFI_pre was significantly higher in the female subgroup. Except for TFI, these trends were maintained in
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data extracted from postchemotherapy CT scans. The mean value of TFI_post was significantly higher
on postchemotherapy CT; however, there was no difference on the preoperative CT. Except for SMIC,
there was no difference between genders in terms of percentage changes over 210 days. The SMIC over
210 days was significantly higher in the female than the male subgroup (Table 2).
Table 1. Comparison of patient characteristics and clinicopathological outcomes according to gender.
Variables Female (n = 67)(%)
Male (n = 100)
(%) p
Age (years) <65 51 (76.1) 63 (63) 0.106
≥65 16 (23.9) 37 (37)
ASA grade I 32 (47.8) 43 (43) 0.928
II 25 (37.3) 39 (39)
III 5 (7.5) 9 (9)
No data 5 (7.5) 9 (9)
BMI (kg/m2) <25 55 (82.1) 66 (66) 0.035
≥25 12 (17.9) 34 (34)
Smoking Yes 0 47 (47) <0.001 a
No 67 (100) 53 (53)
CEA (ng/mL) <5 47 (70.1) 63 (63) 0.430
≥5 20 (29.9) 37 (37)
Tumor location b proximal 28 (41.8) 31 (31) 0.206
distal 39 (58.2) 69 (69)
Operation time (min) <300 50 (74.6) 84 (84) 0.196
≥300 17 (25.4) 16 (16)
Complications No 59 (88.1) 82 (82) 0.4
Yes 8 (11.9) 18 (18)
Tumor size (cm) <5 39 (58.2) 63 (63) 0.645
≥5 28 (41.8) 37 (37)
LVI Absent 37 (55.2) 60 (60) 0.753 a
Present 26 (38.8) 36 (36)
No data 4 (6) 4 (4)
Stage II 10 (14.9) 16 (16) >0.99
III 57 (85.1) 84 (84)
Chemotherapy cycles <10 8 (11.9) 14 (14) 0.879
≥10 59 (88.1) 86 (86)
Abbreviations—BMI: body mass index; ASA: American Society of Anesthesiologists; CEA: carcinoembryonic
antigen; LVI: lymphovascular invasion. a Fisher’s exact test. b Tumor location—proximal: cecum-transverse colon;
distal: descending colon-rectosigmoid junction. Two patients with synchronous colon cancer were classified into
the distal group for statistical reasons.
Table 2. Comparison of preoperative and postchemotherapy values, and changes of anthropometric
values according to gender.
Female (n = 67)
(Mean ± SD)
Male (n = 100)
(Mean ± SD) p
a
Values at preoperative CT
SMI_pre (cm2/m2) 38.9 ± 5.7 47.9 ± 7.5 <0.001
SMR_pre (HU) 41.2 ± 8.8 44.4 ± 7.4 0.012
VFI_pre (cm2/m2) 30.1 ± 22.6 41.1 ± 23.8 0.003
SFI_pre (cm2/m2) 56.0 ± 23.9 36.2 ± 15.6 <0.001
TFI_pre (cm2/m2) 86.1 ± 41 77.3 ± 37.2 0.153
Values at postchemotherapy CT
SMI_post (cm2/m2) 43.5 ± 5.4 51.6 ± 8.1 <0.001
SMR_post (HU) 42.1 ± 7.5 46.5 ± 6.7 <0.001
VFI_post (cm2/m2) 24.8 ± 17.1 30.3 ± 17.6 0.048
SFI_post (cm2/m2) 56.2 ± 22.5 36.2 ± 15.0 <0.001
TFI_post (cm2/m2) 81.0 ± 35.1 66.5 ± 30.7 0.005
Percentage changes over 210 days between preoperative and postchemotherapy CTs
SMIC (%/210 days) 12.8 ± 12.7 8.6 ± 12.0 0.030
SMRC (HU/210 days) 4.1 ± 18.1 5.7 ± 14.5 0.560
VFIC (%/210 days) 12.6 ± 80.9 5.6 ± 124.5 0.660
SFIC (%/210 days) 7.6 ± 33.2 7.3 ± 44.9 0.955
TFIC (%/210 days) 3.6 ± 36.9 −1.0 ± 58.4 0.541
a This comparison was done between values from the female group and values from the male group separately.
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The median changes (%) in SMI, SMR, VFI, SFI, and TFI over 210 days during chemotherapy were
8.7% (p < 0.001), 3.4% (p = 0.001),−19% (p < 0.001),−3.4% (p = 0.936), and−11.9% (p < 0.001), respectively
(Table 3, Figure S2). The cut-off values of SMIC and SMRC were defined at −2%, respectively, whereas
those of VFIC, SFIC, and TFIC were set at −46.57%, −17.03%, and −42.61%, respectively (Figure 1).
Patients were divided into two subgroups during survival analysis based on these values.
Table 3. Distribution of the percentage changes in the skeletal muscle and fat tissues over 210 days
during adjuvant FOLFOX chemotherapy in patients with non-metastatic colon cancer (n = 167).
Value Distribution SMIC SMRC VFIC SFIC TFIC
Minimum −21.3 −34.29 −95.33 −68.94 −76.33
25th percentile 2.75 −4.4 −40.68 −16.04 −24.66
Median 8.7 3.42 −19.04 −3.46 −11.93
75th percentile 17.05 13.40 8.67 19.78 10.33
Maximum 59.8 56.43 648.39 172.59 260.48Cancers 2020, 12, x  5 of 16 
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Figure 1. Determining cut-off values of visceral fat index change (VFIC), subcutaneous fat index change 
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Figure 1. Determining cut-off values of visceral fat index change (VFIC), subcutaneous fat index change
(SFIC), and total fat index change (TFIC) using a X-tile program (n = 167). X-tile plots of the VFIC (A),
SFIC (B), and TFIC ( ) and the points of the variable coloration of the plot represent the str ngth of the
association at each division ranging from low (dark, black) to high (bright, red or green). Red represents
an inverse association between the expression levels and survival of the variables, whereas green
represents a direct association. The optimal cut-off values were defined as the values that produced
the largest χ2 in the Mantel–Cox test, and these points were set as −46.57 (VFIC) (A), −17.03 (SFIC)
(B), and −42.61 (TFIC) (C), respectively. Patients were divided into the two subgroups based on these
values on the following survival analysis.
On univariable analysis, duration of surgery, lymphovascular invasion (LVI), VFIC, and TFIC
were identified as significant predictors of OS (all p < 0.05). In addition, smoking, chemotherapy
cycles, SMR_pre, SMR_post, and SFIC were found to be associated with OS; however, these did not
reach statistical significance (all p < 0.1) (Tables 4 and 5, Supplementary Figures S3–S5). Variables
with p < 0.1 on univariable analysis were entered for multivariable analysis. Low SMR measured on
postchemotherapy CT (HR: 0.32, 95% CI: 0.15–0.70, p = 0.004) and visceral fat loss of at least 46.57%
during FOLFOX chemotherapy (HR: 0.31, 95% CI: 0.14–0.69, p = 0.004) were found to be independent
poor prognostic factors for OS in multivariable analysis. In addition, smoking (HR: 2.25, 95% CI:
1.06–4.77, p = 0.034), a duration of surgery exceeding 300 min (HR: 3.87, 95% CI: 1.80–8.33, p = 0.0005),
and the presence of LVI (HR: 2.46, CI: 1.16–5.18, p = 0.017) were associated with poorer OS (Table 6).
Table 4. Summary of the Kaplan–Meier curve comparison of overall survival according to the
dichotomized groups.
Preoperative CT Postchemotherapy CT Changes/210 Days between Two CTs
SMI_pre low vs.
SMI_pre high p = 0.8
SMI_post low vs.
SMI_post high p = 0.4
SMIC: Loss of 2% or more vs.
Loss of less than 2% p = 0.16
SMR_pre low vs.
SMR_pre high p = 0.066
SMR_post low vs.
SMR_post high p = 0.05
SMRC: Loss of 2% or more
vs. Loss of less than 2% p = 0.94
VFI_pre low vs.
VFI_pre high p = 0.28
VFI_post low vs.
VFI_post high p = 0.89
VFIC: Loss of 46.57% or





SFI_pre high p = 0.45
SFI_post low vs.
SFI_post high p = 0.37
SFIC: Loss of 17.03% or more
vs. Loss of less than 17.03% p = 0.091
TFI_pre low vs.
TFI_pre high p = 0.74
TFI_post low vs.
TFI_post high p = 0.22
TFIC: Loss of 42.61% or more
vs. Loss of less than 42.61% p = 0.0033
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Table 5. Univariable analysis for overall survival.
Univariable Analysis
Variables Hazard Ratio (95% CI) p
Gender Female 1
Male 1.79 (0.83–3.88) 0.137
Age (years) <65 1
≥65 0.76 (0.35–1.65) 0.492
ASA grade 1 1
2 0.77 (0.35–1.70) 0.524
3 0.75 (0.17–3.31) 0.715
No data 1.02 (0.33–3.11) 0.965
BMI (kg/m2) <25 1
≥25 0.59 (0.24–1.44) 0.253
Smoking No 1
Yes 1.83 (0.90–3.72) 0.091
CEA (ng/mL) <5 1
≥5 1.12 (0.55–2.3) 0.743
Tumor location a proximal 1
distal 0.64 (0.32–1.29) 0.219
Operation time (min) <300 1
≥300 2.59 (1.25–5.38) 0.01
Complications No 1
Yes 1.75 (0.78–3.9) 0.169
Tumor size (cm) <5 1
≥5 1.04 (0.51–2.11) 0.912
LVI Absent 1
Present 2.21 (1.07–4.57) 0.03
No data 1.58 (0.35–7.07) 0.545
Stage II 1
III 1.54 (0.53–4.40) 0.419
Chemotherapy cycles <10 1
≥10 0.47 (0.20–1.09) 0.08
SMI_pre Low 1
High 0.91 (0.45–1.82) 0.799
SMR_pre Low 1
High 0.52 (0.25–1.05) 0.070
VFI_pre Low 1
High 1.5 (0.71–3.18) 0.284
SFI_pre Low 1
High 0.75 (0.36–1.57) 0.457
TFI_pre Low 1
High 1.13 (0.53–2.39) 0.746
SMI_post Low 1
High 0.73 (0.35–1.51) 0.401
SMR_post Low 1
High 0.48 (0.23–1.01) 0.055
VFI_post Low 1
High 0.91 (0.27–3.01) 0.887
SFI_post Low 1
High 0.71 (0.34–1.48) 0.372
TFI_post Low 1
High 0.48 (0.14–1.58) 0.229
SMIC Loss of 2% or more 1
Loss of less than 2% 0.54 (0.23–1.27) 0.162
SMRC Loss of 2% or more 1
Loss of less than 2% 0.97 (0.46–2.01) 0.939
VFIC Loss of 46.57% or more 1
Loss of less than 46.57% 0.31 (0.15–0.64) 0.001
SFIC Loss of 17.03% or more 1
Loss of less than 17.03% 0.53 (0.25–1.17) 0.096
TFIC Loss of 42.61% or more 1
Loss of less than 42.61% 0.31 (0.14–0.71) 0.005
Abbreviations—BMI: body mass index; ASA: American Society of Anesthesiologists; CEA: carcinoembryonic
antigen; LVI: lymphovascular invasion; CI: confidence interval. a Tumor location—proximal: cecum-transverse
colon; distal: descending colon-rectosigmoid junction. Two patients with synchronous colon cancer were classified
into the distal group for statistical reasons.
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Table 6. Multivariable analysis for overall survival.
Multivariable Analysis
Variables Hazard Ratio (95% CI) p
Smoking No 1
Yes 2.25 (1.06–4.77) 0.034
Operation time (min) <300 1
≥300 3.87 (1.80–8.33) 0.0005
LVI Absent 1
Present 2.46 (1.16–5.18) 0.017
No data 1.19 (0.26–5.39) 0.818
SMR_post Low 1
High 0.32 (0.15–0.70) 0.004
VFIC Loss of 46.57% or more 1
Loss of less than 46.57% 0.31 (0.14–0.69) 0.004
SFIC Loss of 17.03% or more 1
Loss of less than 17.03% 0.53 (0.23–1.19) 0.128
Abbreviations: LVI: lymphovascular invasion; CI: confidence interval; Factors with p value less than 0.1 in
univariable analysis were entered into multivariable analysis.
3. Discussion
Our study evaluated the clinical significance of body composition measured at different time
points during treatment and its longitudinal alterations in estimating survival within a homogeneous
cohort of patients with non-metastatic colon cancer, who underwent surgery followed by FOLFOX
chemotherapy. Myosteatosis measured on a postchemotherapy CT scan and the loss of at least 46.57%
of visceral fat during chemotherapy were identified as independent adverse prognostic factors. Serial
measurements of body composition and the evaluation of changes may be beneficial in predicting
prognosis in patients with non-metastatic colon cancer. It may therefore be used in modifying follow-up
schedules in these patients with relatively high-risk disease.
Skeletal muscle loss during chemotherapy or chemoradiotherapy has been found to be associated
with poorer survival outcomes in various cancers including those of the breast, pancreas, and cervix [8,9,20].
Reports also suggest that muscle loss during treatment is a significant adverse prognosticator in CRC;
however, this association was mainly derived from patients with metastatic or advanced stage disease
who underwent palliative chemotherapy [14–16,21]. In our study, however, muscle loss (defined as
a loss of more than 2%/210 days) during FOLFOX chemotherapy was not identified as an independent
prognostic factor. This finding is also inconsistent with those of a recent study from our group, which
found muscle loss in excess of 4.2%/100 days during preoperative chemoradiotherapy to be a potential
poor prognostic factor in patients with non-metastatic locally advanced rectal cancer [11]. All patients
in this study had stage II/III colon cancer and had received identical chemotherapy agents in the
post-operative recovery phase, after curative resection. The median change in skeletal muscle bulk over
210 days was not negative (8.7%), and only 22 (13.1%) were classified in the skeletal muscle loss group.
Although direct comparisons may be inaccurate, the overall muscle loss in our cohort was probably not
as severe as that of previous studies, which suggested that muscle loss during treatment was associated
with poor prognosis. It is also known that in patients with metastatic CRC, the frequency of muscle loss
differs based on the intensity of chemotherapy [21]. In addition, the severity of individual weight or
muscle loss may vary according to the stage of cancer cachexia, which is categorized as precachexia,
cachexia, and refractory cachexia according to the international consensus [22]. In view of these findings,
muscle changes may vary according to the stage of disease, treatment modalities, and host response,
and the impact of muscle loss on survival may differ based on different time points in the trajectory of
disease. Further research is required to improve the understanding of the actual impact of muscle loss in
the postoperative follow-up period in patients with relatively early-stage CRC.
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Previous studies demonstrated that myosteatosis, evidenced by a decrease of skeletal muscle
radiodensity, was associated with adverse outcomes in various types of cancers [10,23,24]. Kroenke
and colleagues demonstrated that in patients with CRC, low SMR was associated with higher overall
and CRC-specific mortality [25]. Hopkins et al. also reported that myosteatosis was independently
predictive of OS (HR: 1.53, 95%; CI: 1.19–1.97) [26]. In contrast, several studies have demonstrated no
correlation between myosteatosis and survival outcomes in patients with CRC [27,28]. The discordance
in results across studies is difficult to explain; however, it may be attributed to differences in cut-off
values or methods used to define myosteatosis. In addition, the timing of performing CT scans also
varied between the studies; however, most previous studies used CT scans obtained prior to surgery
or the initiation of palliative chemotherapy. Our study demonstrated that myosteatosis observed on
a postchemotherapy CT scan instead of a preoperative CT scan was associated with adverse outcomes.
This suggested that the clinical impact of radiodensity may depend on the time-point; therefore, serial
measurements are highly recommended for improving the accuracy of predicting survival.
Interestingly, most patients in this study lost visceral fat during the period of chemotherapy; after
adjusting for other clinicopathologic parameters, severe loss of visceral fat was associated with poor
oncologic outcomes. The correlation of visceral fat loss and poor survival outcomes were investigated
in detail in patients with pancreatic cancer. In their study, Dalal and colleagues found that visceral fat
losses exceeding 12.9% correlated with poor overall survival (HR: 2.06, 95% CI: 1.05–4.03, p = 0.034) in
patients with inoperable locally advanced pancreatic cancer, who had undergone chemoradiation; they
suggested that tumor-induced lipolytic factors and pro-inflammatory cytokines played a major role in
adipose tissue wasting [29,30]. In their study, Kays et al. demonstrated that the fat-only loss group had
similar oncologic outcomes to the group with concurrent fat and muscle loss. In a study of patients
with advanced pancreatic ductal adenocarcinoma who underwent chemotherapy with 5-fluorouracil,
leucovorin, irinotecan, and oxaliplatin in the first line, fat-only and concurrent muscle and fat wasting
was also found to be independently predictive of poor prognosis compared with no muscle or fat
wasting [31]. The authors proposed that the different phenotypes of wasting within a homogenous
disease could be related to molecular and genetic differences, which may play particular roles in
specific cachexia; therefore, fat and muscle mass wasting could play equivalent roles [31]. In patients
with CRC, the clinical impact of fat change at consecutive time points has rarely been investigated.
Hopkins and colleagues recently reported that elevated total adiposity was an independent favorable
prognosticator for OS (HR: 0.66, 95% CI: 0.46–0.95, p = 0.024); however, the prognostic impact of visceral
fat changes was not evident [18]. Choe and colleagues found that a reduction in visceral fat during
follow-up was associated with poor survival [19]. These findings appear to concur with the results of
our study; however, certain factors require consideration. These two studies measuring fat changes in
patients with CRC used follow-up CT scans obtained at 2 years after surgery and more than 1 year
after surgery or completion of chemotherapy; patients who developed recurrences within the time
point of the second follow-up CT were excluded from those analyses in those studies [26,32]. In view
of these factors, the results may not be directly applied to clinical decision-making. Although surgery
and post-operative chemotherapy may induce catabolic changes in body composition, the impact is
not permanent and may be reversed within 1–2 years [33]. The absolute distribution of visceral fat
loss in our study may have differed from that of previous studies owing to the different time points of
follow-up CT scans. Our study was able to detect the impact of active body changes immediately on
completion of chemotherapy; this may have been the strength of this study and may provide a more
efficient approach to modulating follow-up schedules. Although the exact underlying mechanism
of severe fat loss during chemotherapy could not be identified and CT scanning is not routinely
performed immediately after completion of chemotherapy, our findings emphasize the clinical utility
of evaluating body composition changes in these relatively high-risk patients in the short term.
In this study, smoking was identified as an important poor prognostic factor. Cigarette smoking
was known to be significantly associated with CRC incidence [34,35]. In addition, a recent meta-analysis
reported random-effects HR estimates (95% CI) for all-cause mortality of 1.26 (1.15–1.37) for current
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smokers compared with never smokers, which indicated that smoking had detrimental effects on
survival even after CRC diagnosis [36]. There is some in vitro evidence that smoking could stimulate
cell metastatic ability by altering epithelial-mesenchymal transition and influence chemotherapy
efficacy by inducing metabolic and epigenetic alterations [37,38]. Smoking showed a strong influence
on the natural history of chronic obstructive pulmonary disease (COPD) and smoking related COPD
was a significant predictor of more visit to emergency room and hospital readmission in colon cancer
patients treated with adjuvant chemotherapy [39,40]. Experimental evidences revealed that smoking
could influence skeletal muscle depletion and some muscle metabolism might be impaired in COPD
patients [41,42]. Based on these effects of smoking, we believe that the trajectory association among
smoking, body composition changes, and chemotherapy tolerance in patients with colon cancer needs
to be further investigated.
In addition, an operation time of more than 300 min was identified as an independent variable
associated with poor oncologic outcomes. Unpredictable intraoperative adverse events can result in a delay
in operation time; thus, operation time might reflect the complex nature of surgery or technical difficulties.
It was reported that technical difficulties during surgery could jeopardize oncologic outcomes in patients
with CRC, although the result was based on laparoscopy colorectal resections [43]. Nevertheless, operation
time might be multifactorial, and our findings need to be validated with more clinical datasets.
This study has certain limitations. First, this was a retrospective single-center study with a relatively
small sample size. Nevertheless, our cohort comprised a homogeneous group; all patients had undergone
curative resection for non-metastatic colon cancer and had received identical adjuvant chemotherapy.
Second, the body composition measured on the preoperative CT scan did not demonstrate any clinical
significance; this may be attributed to the fact that the declared cut-off for sarcopenia, myosteatosis, and
fat obesity used in this study were probably not appropriate for patients with non-metastatic colon cancer
and were not predictive of outcomes in the East Asian population. This study could not provide specific
cut-off values of body composition in this population owing to a limited sample size. Since the relatively
lower BMI in East Asian patients may have a different prognostic impact, further studies are needed to
explore the different strata of body composition. Third, ensuring exact similarities in the abdominal
anatomy between the two selected 2D CT images from the preoperative and postchemotherapy phases
is a particular challenge. Compared to skeletal muscle or subcutaneous fat, measurements of visceral
fat may be particularly influenced by the voluntary movements of the digestive tract. This may have
been reflected by the wider range of visceral fat changes in our study; however, we excluded patients
with evidence of intestinal obstruction on preoperative CT scans to reduce the possibility of incorrect
visceral fat measurements. The limitations of manually measured 2D image-based body composition
may be overcome by using a 3D image-based measurement with machine learning algorithms [44].
Finally, weight loss during chemotherapy was previously reported to be a poor prognostic factor [45].
Visceral fat or muscle loss may translate to loss of body weight; a study of the correlation between these
parameters would be of particular interest. In our study, body weight at the postchemotherapy stage
was not fully recorded in entire cases; this was particularly uninformative. Further studies focusing on
these relationships are warranted.
4. Materials and Methods
This study was conducted after approval of the Institutional Review Board of the Gangnam
Severance Hospital, Yonsei University College of Medicine (Seoul, Korea) (approval no; 3-2017-0099).
The need for informed consent was waived in view of its retrospective design.
Patients with stage III and high-risk stage II colon cancer who underwent curative surgery followed
by FOLFOX chemotherapy between October 2005 and June 2013 were selected. The chemotherapy
schedule given every two weeks was oxaliplatin (85 mg/m2 IV infusion of more than 2 h on day 1),
leucovorin (400 mg/m2 IV infusion of more than 2 h on day 1), and 5-FU (400 mg/m2 IV bolus
injection on day 1, followed by 2400 mg/m2 continuous IV injection over 46 h). A total of 12 cycles
were planned. Patients who underwent at least one cycle of FOLFOX were initially selected in this
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study. Inclusion criteria were patients who had both preoperative and postchemotherapy CT scan
results, body composition data available from the CT scans, and available clinicopathologic and
follow-up data. Exclusion criteria were those who showed intestinal obstruction on the preoperative
CT scans, underwent non-contrast CT alone, received neoadjuvant chemotherapy, and had a history of
inflammatory bowel disease.
4.1. Measured Outcomes of CT-based Anthropometric Values
In our hospital, abdominopelvic CT was performed to evaluate the presence of systemic metastases
before surgery and within 1 month after completion of planned adjuvant chemotherapy. Most of
the enrolled patients underwent postchemotherapy CT after completion of planned chemotherapy.
However, the CT scanning was performed earlier than planned in certain patients with elevated
levels of carcinoembryonic antigen during chemotherapy; this was necessary to detect any potential
systemic metastases.
A single cross-sectional transverse CT image at the L3 vertebra level was selected for analysis.
The portal phase image was initially selected; in cases where it was not available, arterial phase images
were selected to measure the body composition. For evaluation of skeletal muscle, visceral fat, and
subcutaneous fat, this cross-sectional image was entered into the in-house open-source software named
BMI_CT, which was based on the MATLAB Complier (R2014a) Runtime 8.3 (Mathworks Inc., Natick,
MA, USA) software package [46]. This program is available online (https://sourceforge.net/projects/
muscle-fat-area-measurement/; final access date: 30 September 2019) and has been used to measure
body composition in a previous study [47]. In addition, the radiodensity of skeletal muscle was defined
as the mean value of selected skeletal muscle and was measured using open-source three-dimensional
(3D) slicer software (https://slicer.org/) [48]. A randomly selected sub-sample of 30 CT images was
analyzed by two investigators blinded to the clinical outcomes, to calculate the intra-class correlation
coefficients (Supplementary Table S3. The remaining CT images were analyzed by a trained physician.
The skeletal muscle, visceral fat, subcutaneous fat, and SMR were initially measured. The total
fat was defined as the summation of visceral and subcutaneous fat. The skeletal muscle area was
calculated based on the Hounsfield unit (HU) thresholds of −29 and 150. Subcutaneous fat was
calculated based on HU thresholds between −190 and −30, whereas visceral fat was calculated based
on a radiodensity ranging between −150 and −50 HU. The SMI, VFI, SFI (subcutaneous fat index), and
TFI were calculated by dividing each variable by the square of the patient’s height (cm2/m2).
The variables measured from preoperative CT scans were named SMI_pre, SMR_pre, VFI_pre,
SFI_pre, and TFI_pre. The variables measured using postchemotherapy CT scans were defined as
SMI_post, SMR_post, VFI_post, SFI_post, and TFI_post.
The median duration between preoperative CT and surgery was 8 (interquartile range [IQR]:
5–12.5) days. The median duration between preoperative and postchemotherapy CT scans was 217
(IQR: 200.5–231.5) days. The actual change in each variable was divided by the number of days between
CT examinations and multiplied by 210 to account for variations in the durations of scan intervals.
Therefore, the SMIC, SMRC, VFIC, SFIC, and TFIC were defined as follows: (postchemotherapy value
− preoperative value)/preoperative value × 100/(days between postchemotherapy and preoperative
CT scans) × 210 (Figure 2).
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. . efining the Cut-Off Values
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lo S ere efi e as t e reco e e val es base o t e st y by arti a colleag es [49].
The FI, SFI, and TFI ere divided using values of 52.9 cm2/m2 in males and 51.5 cm2/m2 in females,
50 c 2/m2 in males and 42 cm2/m2 in females, and 107.7 cm2/m2 in males and 102.2 c 2/ 2 in fe ales,
respectively; these values were derived from a previous study (Supplementary Table S4 [50]).
Changes in the variables (SMIC, SMRC, VFIC, SFIC, and TFIC) were also considered. The cut-off
values for SMIC and SMRC were set at −2%; considering the potential 2% measurement error range,
these subgroups were defined as “loss of 2% or more” versus “loss of less than 2%” for SMIC and SMRC,
respectively. Owing to the absence of reliable recommendations for changes in fat area, the optimal
cut-off values for VFIC, SFIC, and TFIC were defined as the values that provided the largest χ2 on
the Mantel–Cox test and were defined by the X-tile program (Version 3.6.1, Yale University School of
Medicine, New Haven, CT, USA) [51]. The dichotomized groups were presented based on “loss of
cut-off point or more” and “loss of less than cut-off point.”
4.3. Statistical Analysis
Patients’ clinicopathological characteristics were compared using the chi-square and t-tests for
categorical and continuous variables, respectively. The paired t-test and Wilcoxon signed-rank test
were used to assess changes in body composition. Spearman’s correlation coefficient was used to
assess relationships between continuous variables.
Overall survival (OS) was calculated from the date of surgery to the date of death or the last known
date of being alive. The Kaplan–Meier method with log-rank tests was used to construct the survival
curves. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95%
confidence interval (CI). All variables with a p < 0.1 on univariable analysis were entered for multivariable
analysis. Owing to multicollinearity, we performed forward stepwise selection of variables based on the
Akaike information criterion. A two-sided p < 0.05 was considered statistically significant. All statistical
analyses were performed using SPSS software, version 23.0 (SPSS, Chicago, IL, USA) and R version 3.5.1
(R-project, Institute for Statistics and Mathematics, Vienna, Austria).
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5. Conclusions
In conclusion, in patients with non-metastatic colon cancer who underwent FOLFOX adjuvant
chemotherapy, our study demonstrated that severe visceral fat loss and myosteatosis detected during
the postchemotherapy period could be used to stratify patients at high-risk of mortality. Further studies
are needed to investigate whether a reversal of these changes may improve survival. Our findings
represent a novel association between body composition and patient outcomes and suggest that
changes in composition may be used as indicators during surveillance. Further prospective studies in
larger cohorts are needed to validate our findings.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/1/60/s1,
Table S1. Absolute changes in body composition during FOLFOX adjuvant chemotherapy; Table S2. Correlation
coefficient of changes in body composition during FOLFOX adjuvant chemotherapy; Table S3. Intraclass correlation
coefficients according to the body compositions (n = 30); Table S4. Cut-off values from previous studies adopted
in this study; Figure S1. Distribution of number of completed cycles of FOLFOX chemotherapy; Figure S2.
Distribution of the percentage changes in body composition over 210 days (n = 167); Figure S3. Kaplan–Meier
curve comparison of overall survival according to the dichotomized anthropometric variables measured at the
preoperative CT (n = 167); Figure S4. Kaplan–Meier curve comparison of overall survival according to the
dichotomized anthropometric variables measured at the postchemotherapy CT (n = 167); Figure S5. Kaplan–Meier
curve comparison of overall survival according to the dichotomized changes of anthropometric variables during
chemotherapy (n = 167).
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